Expression of MAGE-A12 in oral squamous cell carcinoma


Mollaoglu N., Vairaktaris E., Nkenke E., Neukam F. W., Ries J.

DISEASE MARKERS, cilt.24, sa.1, ss.27-32, 2008 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 24 Sayı: 1
  • Basım Tarihi: 2008
  • Doi Numarası: 10.1155/2008/359840
  • Dergi Adı: DISEASE MARKERS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.27-32
  • Anahtar Kelimeler: nested RT-PCR, MAGE-A12 gene expression, oral squamous cell carcinoma, diagnostic, therapy, CANCER-IMMUNOTHERAPY, MELANOMA PATIENTS, DENDRITIC CELLS, GENES, ANTIGENS, HEAD, NECK, PEPTIDE, FAMILY, DIAGNOSIS
  • Gazi Üniversitesi Adresli: Evet

Özet

Melanoma associated-A antigens (MAGE-A) are silent in normal tissues except testis. However, they are activated in a variety of different tumors. Thus, their expression is highly specific to cancer cells. Reverse transcription-nested polymerase chain reaction (RT-nPCR) is a highly sensitive technique that has been used successfully for the detection of MAGE genes in tissue samples. The aim of the study is to analyze the expression rate of MAGE-A12 in oral squamous cell carcinoma (OSCC) using a high sensitive RT-nPCR. Total of 57 tissue samples obtained from patients with OSCC and 20 normal oral mucosal (NOM) probes of otherwise healthy volunteers were included to this study. No expression of MAGE-A12 was observed in the non-neoplastic NOM tissues. MAGE-A12 was expressed in 49.1% of the investigated tumor samples. The correlation between malignant lesion and MAGE-A12 detection was significant (p < 0.001). It is concluded that results of this study may indicate MAGE-A12 as a useful additional diagnostic marker especially for the early detection of OSCC distinguishing neoplastic transformation and detection of occult and/or rare disseminated cancer cells. In addition, MAGE-A12 expression in OSCC may also determine a new immunotherapeutic target and might be warranted to develop vaccine for OSCC.